Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
Tucker ER, Jiménez I, Chen L, Bellini A, Gorrini C, Calton E, Gao Q, Che H, Poon E, Jamin Y, Martins Da Costa B, Barker K, Shrestha S, Hutchinson JC, Dhariwal S, Goodman A, Del Nery E, Gestraud P, Bhalshankar J, Iddir Y, Saberi-Ansari E, Saint-Charles A, Geoerger B, Marques Da Costa ME, Pierre-Eugène C, Janoueix-Lerosey I, Decaudin D, Nemati F, Carcaboso AM, Surdez D, Delattre O, George SL, Chesler L, Tweddle DA, Schleiermacher G.
Tucker ER, et al. Among authors: saint charles a.
Clin Cancer Res. 2023 Apr 3;29(7):1317-1331. doi: 10.1158/1078-0432.CCR-22-2274.
Clin Cancer Res. 2023.
PMID: 36602782
Free PMC article.